HTG Molecular Diagnostics, Inc. HTGM
At closeJun 14, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 1.06M
- Revenue (ttm)
- 6.21M
- Shares out
- 2.21M
- Forward P/E
- -0.45
- Volume
- 725.43K
- Open
- 0.5701
- Previous close
- 0.48
- Day's range
- 0.48 – 0.48
- Beta
- 0.99
- Analysts
- Buy
- Price target
- 6.00 (+1150.0%)
- Earnings date
- Aug 10, 2023
1Y -6.4800 (-93.10%)
Key statistics
- Enterprise value
- 2.56M
- PEG ratio
- 0.00
- Price / sales
- 0.17
- Price / book
- 2.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -12.80%
- Free cash flow
- -9.91M
- Total cash
- 6.56M
- Total debt
- 7.80M
- Return on equity
- -343.21%
- Short % of float
- 0.12%
- 50-day average
- 1.98
- 200-day average
- 4.21
Analyst view
Consensus: buy
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -1.84.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -1.84 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | -1.94 | — | — | — |
| Apr 4, 2023 | Dec 1, 2022 | -2.41 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -6.24 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -6.96 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -8.52 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 19, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Apr 3, 2023 | HC Wainwright & Co. | main | — | Buy |
| Aug 15, 2022 | HC Wainwright & Co. | main | — | Buy |
| May 16, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 31, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 30, 2022 | Craig-Hallum | main | — | Buy |
About HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- htgmolecular.com
News
Stocks That Hit 52-Week Lows On Tuesday - Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today? 
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket 
Stocks That Hit 52-Week Lows On Tuesday - Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session 
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series 
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Your note
Sign in to keep a note on HTGM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARAT STEPHEN | Officer | Sale | Jun 7, 2023 | 421 |
| GODLEWSKI LAURA LEE | Officer | Stock Award(Grant) | Dec 8, 2022 | 4,904 |
| GRIFFIN MICHELLE RENEE | Director | Stock Award(Grant) | Aug 13, 2019 | 2,500 |
| HANHAM ANN F | Director | Stock Award(Grant) | Aug 13, 2019 | 7,304 |
| HARDISON DONALD M | Director | Stock Award(Grant) | Aug 13, 2019 | 12,500 |
| JOHNSON TIMOTHY B | Officer and Director | Stock Award(Grant) | Dec 9, 2020 | 16,847 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 0.66% | 14,692 | 7.05K | Mar 30, 2023 |
| UBS Group AG | 0.23% | 5,198 | 2.50K | Mar 30, 2023 |
| Tower Research Capital LLC (TRC) | 0.07% | 1,481 | 710 | Mar 30, 2023 |
| Blackrock Inc. | 0.06% | 1,289 | 618 | Mar 30, 2023 |
| Morgan Stanley | 0.04% | 884 | 424 | Mar 30, 2023 |
| Highmark Wealth Management LLC | 0.03% | 580 | 278 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.27% | 5,909 | 2.84K | Dec 30, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.21% | 4,603 | 2.21K | Feb 27, 2023 |
| Fidelity Extended Market Index Fund | 0.11% | 2,421 | 1.16K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 776 | 372 | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.01% | 313 | 150 | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.01% | 249 | 119 | Feb 27, 2023 |